205 related articles for article (PubMed ID: 28008178)
21. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
[TBL] [Abstract][Full Text] [Related]
22. RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation.
Bednarski JJ; Nickless A; Bhattacharya D; Amin RH; Schlissel MS; Sleckman BP
J Exp Med; 2012 Jan; 209(1):11-7. PubMed ID: 22201128
[TBL] [Abstract][Full Text] [Related]
23. Pinning down myeloma with Pim2 inhibitors!
Neri P; Bahlis NJ
Blood; 2013 Aug; 122(9):1534-6. PubMed ID: 23990611
[No Abstract] [Full Text] [Related]
24. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
25. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J; Hiasa M; Oda A; Harada T; Nakamura S; Amachi R; Tenshin H; Iwasa M; Fujii S; Kagawa K; Miki H; Kurahashi K; Yoshida S; Endo I; Haneji T; Matsumoto T; Abe M
Br J Haematol; 2018 Feb; 180(4):581-585. PubMed ID: 27748523
[No Abstract] [Full Text] [Related]
26. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
Mikkers H; Nawijn M; Allen J; Brouwers C; Verhoeven E; Jonkers J; Berns A
Mol Cell Biol; 2004 Jul; 24(13):6104-15. PubMed ID: 15199164
[TBL] [Abstract][Full Text] [Related]
27. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
28. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
29. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K; Obkircher M; Neureiter D; Parteli J; Zelle-Rieser C; Maizner E; Kern J; Hermann M; Hamacher F; Merkel O; Wacht N; Zidorn C; Scheideler M; Greil R
J Mol Med (Berl); 2012 Jun; 90(6):681-93. PubMed ID: 22205266
[TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
31. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
32. PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma.
Wang JC; Chen DP; Lu SX; Chen JB; Wei Y; Liu XC; Tang YH; Zhang R; Chen JC; Kan A; Xu L; Zhang YJ; Hou J; Kuang DM; Chen MS; Zhou ZG
Cancer Res; 2022 Sep; 82(18):3307-3320. PubMed ID: 35802648
[TBL] [Abstract][Full Text] [Related]
33. Roles of Pim-3, a novel survival kinase, in tumorigenesis.
Mukaida N; Wang YY; Li YY
Cancer Sci; 2011 Aug; 102(8):1437-42. PubMed ID: 21518143
[TBL] [Abstract][Full Text] [Related]
34. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
35. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
36. pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1.
Wingett D; Long A; Kelleher D; Magnuson NS
J Immunol; 1996 Jan; 156(2):549-57. PubMed ID: 8543805
[TBL] [Abstract][Full Text] [Related]
37. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
38. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.
Hammerman PS; Fox CJ; Cinalli RM; Xu A; Wagner JD; Lindsten T; Thompson CB
Cancer Res; 2004 Nov; 64(22):8341-8. PubMed ID: 15548703
[TBL] [Abstract][Full Text] [Related]
39. Combining chemical and genetic approaches for development of responsive FRET-based sensor systems for protein kinases.
Manoharan GB; Enkvist E; Uri A
Biophys Chem; 2016 Apr; 211():39-48. PubMed ID: 26874332
[TBL] [Abstract][Full Text] [Related]
40. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
